Boston Scientific Corporation (BSX) announced significant corporate actions, expanding its Board of Directors from ten to twelve members with the appointment of Catherine R. Smith and Christophe P. Weber, effective February 18, 2026. Concurrently, the board approved an increase of $4.0 billion to its existing share repurchase authorization, bringing the total available to $5.0 billion. These moves aim to strengthen oversight and provide flexibility for future stock buybacks, with the new directors bringing diverse leadership experience to key board committees.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Boston Scientific (BSX) expands board, approves $5.0B share repurchase plan
Boston Scientific Corporation (BSX) announced significant corporate actions, expanding its Board of Directors from ten to twelve members with the appointment of Catherine R. Smith and Christophe P. Weber, effective February 18, 2026. Concurrently, the board approved an increase of $4.0 billion to its existing share repurchase authorization, bringing the total available to $5.0 billion. These moves aim to strengthen oversight and provide flexibility for future stock buybacks, with the new directors bringing diverse leadership experience to key board committees.